Related Articles
Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells
Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients
Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma‑associated mRNAs in high‑risk neuroblastoma patients
Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients
Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers